UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours

McMeish, I; Kanfer, EJ; Haynes, R; Giles, C; Harland, SJ; Driver, D; Rustin, GJS; ... Seckl, MJ; + view all (2004) Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours. British Journal of Cancer , 90 (6) pp. 1169-1175.

Full text not available from this repository.

Abstract

High-dose regimes containing etoposide, carboplatin and an oxazaphospharine can salvage 30-40% of patients with relapsed or refractory male germ cell tumours (GCTs). The additional benefit of paclitaxel in such high-dose therapy has not been tested, Between March 1995 and November 2002, 36 male GCT patients were treated with Carbop-EC-T (paclitaxel 75 mg m(-2), etoposide 450 mg m(-2), carboplatin AUC 10 on days -7, -5 and - 3 and cyclophosphamide 60 mg kg(-1) on days -5 and -3) followed by peripheral blood stem cell infusion (day 0). The 1-year overall survival rate for all patients is 67% (median follow-up 29 months). For the 24 patients with cisplatin-sensitive disease, the 1-year overall and event-free survivals are 88 and 64%, respectively. For those with cisplatin refractory or absolutely refractory disease, the 1-year overall survival is 25%. In all, 12 patients relapsed at a median duration of 5 months, 11 of whom have died. There were also six treatment- related deaths, five associated with pneumonitis. Pulmonary toxicity has been reported with paclitaxel in other high-dose regimes. Since altering our protocol so that paclitaxel is infused over 24 In with steroid prophylaxis, only one of 18 patients (13 testicular GCTs and five other tumour types) has had a treatment-related death. Our results suggest that Carbop- EC-T may enable a greater proportion of patients with relapsed and refractory GCTs to enter long-term remission

Type: Article
Title: Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours
Additional information: WoS ID: 000220846900012 JournalEnglishArticle35NATURE PUBLISHING GROUPBEYER J, 2002, ANN ONCOL, V13, P599; BEYER J, 1996, J CLIN ONCOL, V14, P2638; BHATIA S, 2000, J CLIN ONCOL, V18, P3346; BOKEMEYER C, 1999, J CLIN ONCOL, V17, P3450; BOWER M, 1997, ANN ONCOL, V8, P477; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748; DAMON L, 1997, BLOOD S1 2, V90, P4356; DEWIT R, 1999, INT J CANCER, V83, P831; DUNSFORD ML, 1999, ANN ONCOL, V10, P943; FLECHON A, 1999, INT J CANCER, V83, P844; FUJIMORI K, 1998, ONCOLOGY-BASEL, V55, P340; GOLDBERG HL, 1995, J CLIN ONCOL, V13, P534; HINTON S, 2002, J CLIN ONCOL, V20, P1859; KANFER EJ, 1998, BRIT J CANCER, V78, P928; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457; KHAN A, 1997, ANN PHARMACOTHER, V31, P1471; LOEHRER PJ, 1998, J CLIN ONCOL, V16, P2500; LYTTELTON MPA, 1998, BRIT J CANCER, V77, P1672; MEAD GM, 1997, J CLIN ONCOL, V15, P594; MOTZER RJ, 2000, J CLIN ONCOL, V18, P1173; MOTZER RJ, 2000, J CLIN ONCOL, V18, P2413; MOTZER RJ, 1994, J CLIN ONCOL, V12, P2277; NICHOLS C, 1999, INT J CANCER, V83, P841; NICHOLS CR, 1989, J CLIN ONCOL, V7, P932; PRINCE HM, 2000, BONE MARROW TRANSPL, V26, P955; RICK O, 1998, EUR J CANCER, V34, P1883; RICK O, 1999, INT J CANCER, V83, P839; RICK O, 2001, J CLIN ONCOL, V19, P81; ROSTI G, 2002, P AN M AM SOC CLIN, V21, P716; SIEGERT W, 1994, J CLIN ONCOL, V12, P1223; THOMAS AL, 2000, EUR J CANCER, V36, P2329; TONER GC, 2001, LANCET, V357, P739; WANG GS, 2001, BRIT J CANCER, V85, P1247; WILLIAMS SD, 1992, ANN ONCOL, V3, P780; ZIMMERMAN TM, 1998, CANCER, V83, P15400MAR 22812NTLONDONSeckl MJ Charing Cross Hosp, Imperial Coll Sch Med, Dept Med Oncol, Fulham Palace Rd, London W6 8RF, EnglandBRIT J CANCERMACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
Keywords: BREAST- CANCER, CANCER, CARBOPLATIN, CHEMOTHERAPY, cisplatin resistance, DISEASE, ETOPOSIDE, germ cell tumour, high-dose chemotherapy, HYPERSENSITIVITY PNEUMONITIS, IFOSFAMIDE, MATCHED-PAIR ANALYSIS, paclitaxel, PHASE-I/II, RENAL-FUNCTION, SALVAGE CHEMOTHERAPY, SURVIVAL, THERAPY
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: http://discovery.ucl.ac.uk/id/eprint/70203
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item